Currently, there are 266.14M common shares owned by the public and among those 240.33M shares have been available to trade.
The company’s stock has a 5-day price change of 31.85% and 13.11% over the past three months. AUTL shares are trading -11.91% year to date (YTD), with the 12-month market performance down to -48.12% lower. It has a 12-month low price of $1.11 and touched a high of $5.00 over the same period. AUTL has an average intraday trading volume of 1.97 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 38.97%, 42.62%, and -21.15% respectively.
Institutional ownership of Autolus Therapeutics plc ADR (NASDAQ: AUTL) shares accounts for 54.25% of the company’s 266.14M shares outstanding.
It has a market capitalization of $550.91M and a beta (3y monthly) value of 1.73. The earnings-per-share (ttm) stands at -$0.89. Price movements for the stock have been influenced by the stock’s volatility, which stands at 3.97% over the week and 5.69% over the month.
Earnings per share for the fiscal year are expected to decrease by -3.38%, and 22.43% over the next financial year. EPS should grow at an annualized rate of 22.26% over the next five years, compared to 21.36% over the past 5-year period.
Looking at the support for the AUTL, a number of firms have released research notes about the stock. Goldman stated their Buy rating for the stock in a research note on November 18, 2024, with the firm’s price target at $7-$7.60. Redburn Atlantic coverage for the Autolus Therapeutics plc ADR (AUTL) stock in a research note released on November 15, 2024 offered a Buy rating with a price target of $13. Deutsche Bank was of a view on November 09, 2023 that the stock is Buy, while Wells Fargo gave the stock Overweight rating on March 27, 2023, issuing a price target of $8. Bryan Garnier on their part issued Buy rating on March 17, 2023.
